Skip to content
The Policy VaultThe Policy Vault

sunitinib malateMedica

Differentiated thyroid carcinoma (papillary, follicular, oncocytic/Hürthle cell)

Initial criteria

  • age ≥ 18 years
  • Patient has papillary or follicular thyroid carcinoma that is refractory to radioactive iodine therapy OR has oncocytic (formerly Hürthle cell) carcinoma

Approval duration

1 year